AbCellera Biologics (ABCL) Operating Income: 2020-2023
Historic Operating Income for AbCellera Biologics (ABCL) over the last 4 years, with Dec 2023 value amounting to -$66.1 million.
- AbCellera Biologics' Operating Income fell 74.85% to -$66.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$237.2 million, marking a year-over-year decrease of 209.56%. This contributed to the annual value of -$314.8 million for FY2024, which is 32.70% down from last year.
- According to the latest figures from Q4 2023, AbCellera Biologics' Operating Income is -$66.1 million, which was down 20.34% from -$54.9 million recorded in Q3 2023.
- AbCellera Biologics' 5-year Operating Income high stood at $224.9 million for Q1 2022, and its period low was -$66.1 million during Q4 2023.
- Over the past 3 years, AbCellera Biologics' median Operating Income value was -$18.2 million (recorded in 2021), while the average stood at $15.3 million.
- Examining YoY changes over the last 5 years, AbCellera Biologics' Operating Income showed a top increase of 7,549.29% in 2021 and a maximum decrease of 1,489.14% in 2021.
- Over the past 4 years, AbCellera Biologics' Operating Income (Quarterly) stood at $160.8 million in 2020, then crashed by 49.28% to $81.6 million in 2021, then crashed by 146.32% to -$37.8 million in 2022, then crashed by 74.85% to -$66.1 million in 2023.
- Its Operating Income was -$66.1 million in Q4 2023, compared to -$54.9 million in Q3 2023 and -$51.4 million in Q2 2023.